The growing influence of payors means biopharma companies are grappling with how to incorporate the impact of reimbursement on a product's market opportunity when structuring deals, executives said at the BIO-Windhover Pharmaceutical Strategic Outlook conference in New York City on February 24.
For several years, pharma has been slowly, and sometimes inconsistently, incorporating reimbursement concerns into clinical development programs at earlier stages in order to amass data to maximize the appeal of...